...
首页> 外文期刊>Chemical research in toxicology >Absence of DNA Adduct in the Leukocytes from Breast Cancer Patients Treated with Toremifene
【24h】

Absence of DNA Adduct in the Leukocytes from Breast Cancer Patients Treated with Toremifene

机译:托瑞米芬治疗乳腺癌患者白细胞中无DNA加合物

获取原文
获取原文并翻译 | 示例
           

摘要

Tamoxifen(TAM)causes cancer in rat liver and human endometrium,whereas the carcinogenicity of its chlorinated analogue toremifene(TOR)has not been observed.To elucidate the genotoxicity of TOR,the capability of forming DNA adducts by TOR was examined in the leukocytes of patients treated with TOR.Leukocytes were collected from 27 breast cancer patients(57.7 +-11.4 years old)taking TOR(40 mg/day for 25 patients,80 mg/day for one patient,and 120 mg/day for one patient;average duration,approx12 months)and 20 untreated breast cancer patients(58.2 +-12.3 years old).The DNA extracted was analyzed by ~(32)P-postlabeling/high-performance liquid chromatography.No DNA adducts were detected in the leukocytes of either TOR-treated or nontreated patients.Our results contrast to the previous observation detecting TAM-DNA adducts in several patients treated with TAM,indicating that TOR is less genotoxic to humans.
机译:他莫昔芬(TAM)在大鼠肝脏和人子宫内膜中致癌,但未观察到其氯化类似物托瑞米芬(TOR)的致癌性。为阐明TOR的遗传毒性,研究了TOR在白细胞中形成DNA加合物的能力。接受TOR治疗的患者。从27名乳腺癌患者(57.7±-11.4岁)中收集白细胞,接受TOR治疗(25例患者每天40 mg,1例患者每天80 mg,1例患者每天120 mg;平均)持续时间(约12个月)和20例未经治疗的乳腺癌患者(58.2 + -12.3岁)。提取的DNA进行了〜(32)P后标记/高效液相色谱分析。在两个患者的白细胞中均未检测到DNA加合物TOR治疗或未治疗的患者。我们的结果与先前观察到的在几位接受TAM治疗的患者中检测到TAM-DNA加合物的观察结果相反,表明TOR对人类的遗传毒性较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号